HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 263-275

  Gajria, Devika ^a   Chandarlapaty, Sarat ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

17 AAG; breast cancer; HER2; lapatinib; p95 HER2; pertuzumab; resistance; tanespimycin; targeted therapy; trastuzumab

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BKM 120; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; GEMCITABINE; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TANESPIMYCIN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB MAYTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CONJUGATION; DIARRHEA; DRUG BINDING; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; MONOTHERAPY; NAUSEA; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 79952162826     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.226     Document Type: Review

References (109)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 235, 177-182 (1987).
2. Andrulis IL, Bull SB, Blackstein ME et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol. 16, 1340-1349 (1998).
3. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 16, 462-469 (1998).
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. 2, 127-137 (2001).
5. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8 (2001).
6. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
7. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
8. Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J. Clin. Oncol. 26, 1642-1649 (2008).
9. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 358, 1409-1411 (2008).
10. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9, 1165-1172 (1989).
11. Cobleigh M, Vogel C, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
12. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
13. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
15. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA 8-11 December 2005.
16. Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J. Clin. Oncol. 28, 4307-4315 (2010).
17. Cuello M, Ettenberg SA, Clark AS et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892-4900 (2001).
18. Junttila TT, Akita RW, Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429-440 (2009). Discriminates mechanisms whereby trastuzumab and pertuzumab antagonize HER2 signaling.
19. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749 (2001).
20. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141 (2002).
21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
22. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259-267 (2006).
23. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin. Oncol. 28, 27-32 (2001).
24. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/Neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998). Pivotal preclinical work demonstrating the combined efficacy of chemotherapy with trastuzumab.
25. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/Neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241-2251 (1999).
26. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96, 739-749 (2004).
27. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19, 2587-2595 (2001).
28. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479-7491 (2009).
29. Pegram M. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? Clin. Breast Cancer 8(Suppl. 3), S121-S130 (2008).
30. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004 (2005).
31. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004). Key demonstration that loss of PTEN mediates resistance to trastuzumab.
32. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14, 672-676 (2001).
33. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007). Demonstrated that the PI3K pathway activation status is the predictive biomarker able to identify patients at risk for progression after trastuzumab therapy.
34. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005). Identification of a significant subset of HER2-amplified tumors with coincident PIK3CA mutations.
35. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68, 6084-6091 (2008).
36. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177, 1647-1656 (2010).
37. Chandarlapaty S, King T, Sakr R et al. Hyperactivation of the PI3K - AKT pathway commonly underlies resistance to trastuzumab in HER2 amplified breast cancer. Cancer Res. (Meeting Abstracts) 69, S709 (2009).
38. Sakr RA, Barbashina V, Morrogh M et al. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 18, 371-374 (2010).
39. Kalinsky K, Jacks LM, Heguy A et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15, 5049-5059 (2009).
40. Saez R, Molina MA, Ramsey EE et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 12, 424-431 (2006).
41. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628-638 (2007). Demonstration of the association between p95-HER2 expression and trastuzumab resistance in human tumor samples.
42. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933-8938 (2003). Experiments demonstrate the essential functions for HER3 in HER2-overexpressing tumors.
43. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
44. Lee-Hoeflich ST, Crocker L, Yao E et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887 (2008).
45. Motoyama AB, Hynes NE, Lane HA. The effificacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62, 3151-3158 (2002).
46. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29, 5193-5203 (2010).
47. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23, 646-653 (2004).
48. Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007).
49. Adams CW, Allison DE, Flagella K et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55, 717-727 (2006).
50. Ritter CA, Perez-Torres M, Rinehart C et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13, 4909-4919 (2007).
51. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl Cancer Inst. 93, 1852-1857 (2001).
52. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
53. Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of HER2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008).
54. Liu L, Greger J, Shi H et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871-6878 (2009).
55. Zhuang G, Brantley-Sieders DM, Vaught D et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70, 299-308 (2010).
56. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
57. O'Brien NA, Browne BC, Chow L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther. 9, 1489-1502 (2010). Demonstrates that PI3K pathway activation does not predict resistance to lapatinib therapy.
58. Xia W, Husain I, Liu L et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 67, 1170-1175 (2007).
59. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999-3005 (2008).
60. Burstein HJ, Storniolo AM, Franco S et al. A Phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 19, 1068-1074 (2008).
61. Blackwell KL, Pegram MD, Tan-Chiu E et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20, 1026-1031 (2009).
62. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
63. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008).
64. Amin DN, Sergina N, Ahuja D et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2, 16ra7 (2010).
65. Scaltriti M, Chandarlapaty S, Prudkin L et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin. Cancer Res. 16, 2688-2695 (2010). Shows that lapatinib therapy is effective for patients with p95-HER2 expressing breast tumors.
66. Johnston S, Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 26, 1066-1072 (2008).
67. Migliaccio I, Gutierrez M, Wu M-F et al. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer. Cancer Res. (Meeting Abstracts) 69, S34 (2009).
68. Wong KK, Fracasso PM, Bukowski RM et al. A Phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 15, 2552-2558 (2009).
69. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301-1307 (2010).
70. Chow L, Gupta S, Hershman D et al. Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in ErbB2+ metastatic breast cancer. Cancer Res. (Meeting Abstracts) 69, S5081 (2009).
71. Awada A, Dirix L, Beck J et al. Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in ErbB2+ metastatic breast cancer. Cancer Res. (Meeting Abstracts) 69, S5095 (2009).
72. Saura C, Martin M, Moroose R et al. Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a Phase 1/2 study. Cancer Res. (Meeting Abstracts) 69, S5108 (2009).
73. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a Phase 1/2 study. Cancer Res. (Meeting Abstracts) 69, S243 (2009).
74. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/Neu monoclonal antibody plus cisplatin in patients with HER2/Neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671 (1998).
75. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin. Breast Cancer 4, 120-125 (2003).
76. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer 5, 52-58; discussion 59-62 (2004).
77. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 22, 1063-1070 (2004).
78. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130 (2010). Clinical trial demonstrating that combined HER2 blockade with trastuzumab and lapatinib improves clinical outcomes after progression on trastuzumab.
79. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J. Clin. Oncol. 27, 1999-2006 (2009). Clinical trial demonstrating that continuing trastuzumab even after cancer progression on trastuzumab has clear benefits.
80. O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest. New Drugs DOI: 10.1007/s10637-010-9415-5 (2010) (Epub ahead of print).
81. Scaltriti M, Verma C, Guzman M et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803-814 (2009).
82. Storniolo AM, Pegram MD, Overmoyer B et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 26, 3317-3323 (2008).
83. Smith KL, Dang C, Seidman AD. Cardiac dysfunction associated with trastuzumab. Expert Opin. Drug Saf. 5, 619-629 (2006).
84. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127-137 (2002).
85. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330-9336 (2009).
86. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010).
87. Baselga J, Cortes J, Fumoleau P et al. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Cancer Res. (Meeting Abstracts) 69, s5114 (2009).
88. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 14, 2710-2716 (2008).
89. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
90. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (TDM-1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1090-x (2010) (Epub ahead of print).
91. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698-2704 (2010).
92. Krop IE, LoRusso P, Miller KD et al. A Phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (TDM-1) in patients (PTS) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. Ann. Oncol. 277O (2010).
93. Vogel C, Burris HA, Limentani S et al. A Phase II study of trastuzumab-DM1 (TDM-1), a HER2 antibody-drug conjugate in patients with HER2+ metastatic breast cancer: final results. J. Clin. Oncol. 27, s1017 (2009).
94. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21, 1159-1166 (2002).
95. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2, 3-24 (2002).
96. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 62, 3132-3137 (2002).
97. Chandarlapaty S, Sawai A, Ye Q et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 14, 240-248 (2008).
98. Chandarlapaty S, Scaltriti M, Angelini P et al. Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325-334 (2010).
99. Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a Phase I dose - escalation study. J. Clin. Oncol. 25, 5410-5417 (2007).
100. Modi S, Sugarman S, Stopeck AT et al. Phase II trial of the Hsp90 inhibitor tanespimycin + trastuzumab in patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 26, s1027 (2008).
101. Miller K, Rosen L, Modi S et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab J. Clin. Oncol. 25, s1115 (2007).
102. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov. Today 13, 38-43 (2008).
103. Burris H, Rodon J, Sharma S et al. First-in-human Phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 28, 3005 (2010).
104. Baselga J, De Jonge MJ, Rodon J et al. A first-in-human Phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 28, 3003 (2010).
105. Tolcher AW, Yap TA, Fearen I et al. A Phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. (Meeting Abstracts) 27, 3503 (2009).
106. Andre F, Campone M, Hurvitz SA et al. Multicenter Phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J. Clin. Oncol. (Meeting Abstracts) 26, 1003 (2008).
107. Dalenc F, Campone M, Hupperets P et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter Phase II clinical trial. J. Clin. Oncol. (Meeting Abstracts) 28, 1013 (2010).
108. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22, 2336-2347 (2004).
109. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314-5322 (2005).